Skip to main content
Top
Published in: Annals of Surgical Oncology 6/2010

01-06-2010 | Pancreatic Tumors

Parenchyma-Preserving Resections for Small Nonfunctioning Pancreatic Endocrine Tumors

Authors: Massimo Falconi, MD, Alessandro Zerbi, MD, Stefano Crippa, MD, Gianpaolo Balzano, MD, Letizia Boninsegna, MD, Vanessa Capitanio, MD, Claudio Bassi, MD, Valerio Di Carlo, MD, Paolo Pederzoli, MD

Published in: Annals of Surgical Oncology | Issue 6/2010

Login to get access

Abstract

Background

Parenchyma-preserving resections (PPRs), including enucleation and middle pancreatectomy (MP), are accepted procedures for insulinomas, but their role in the treatment of nonfunctioning pancreatic endocrine tumors (NF-PETs) is debated. The aim of this study was to evaluate perioperative and long-term outcomes after PPRs for NF-PETs.

Methods

All patients who underwent PPRs for NF-PETs between 1990 and 2005 were included. Patients with multiple endocrine neoplasia type 1 were excluded.

Results

Overall, 50 patients (23 men, 27 women, median age 59 years) underwent 26 enucleations and 24 MP. A total of 58% of NF-PETs were incidentally discovered. Median size of the tumors was 13.5 mm with no preoperative suspicion of malignancy in all patients. Overall morbidity and pancreatic fistula rates were 58 and 50%, respectively. Reoperation rate was 4%, with no mortality. Postoperative complications were higher in the MP group. At pathology, there were 34 (68%) benign lesions, 13 (26%) neoplasms of uncertain behavior, and 3 (6%) well-differentiated carcinomas. Forty-one patients (82%) had tumors ≤2 cm in size. Only eight patients (16%) had at least one lymph node removed. After a median follow-up of 58 months, no patient died of disease. Overall, four patients (8%) experienced tumor recurrence after a mean of 68 months. The incidence of exocrine/endocrine insufficiency was 8%.

Conclusions

PPRs are generally safe and effective procedures for treating small NF-PETs. However, better selection criteria must be identified, and lymph node sampling should be performed routinely to avoid understaging. Long-term follow-up evaluation (>5 years) is of paramount importance given the possible risk of late recurrence.
Literature
1.
2.
go back to reference Norton JA. Surgery for primary pancreatic neuroendocrine tumors. J Gastrointest Surg. 2006;10:327–31.CrossRefPubMed Norton JA. Surgery for primary pancreatic neuroendocrine tumors. J Gastrointest Surg. 2006;10:327–31.CrossRefPubMed
3.
go back to reference Falconi M, Plockinger U, Kwekkeboom DJ, et al. Well-differentiated pancreatic nonfunctioning tumors/carcinoma. Neuroendocrinology. 2006;84:196–211.CrossRefPubMed Falconi M, Plockinger U, Kwekkeboom DJ, et al. Well-differentiated pancreatic nonfunctioning tumors/carcinoma. Neuroendocrinology. 2006;84:196–211.CrossRefPubMed
4.
go back to reference La Rosa S, Klersy C, Uccella S, et al. Improved histologic and clinicopathologic criteria for prognostic evaluation of pancreatic endocrine tumors. Hum Pathol. 2009;40:30–40.CrossRefPubMed La Rosa S, Klersy C, Uccella S, et al. Improved histologic and clinicopathologic criteria for prognostic evaluation of pancreatic endocrine tumors. Hum Pathol. 2009;40:30–40.CrossRefPubMed
5.
go back to reference Dralle H, Krohn SL, Karges W, et al. Surgery of resectable nonfunctioning neuroendocrine pancreatic tumors. World J Surg. 2004;28:1248–60.CrossRefPubMed Dralle H, Krohn SL, Karges W, et al. Surgery of resectable nonfunctioning neuroendocrine pancreatic tumors. World J Surg. 2004;28:1248–60.CrossRefPubMed
6.
go back to reference Park BJ, Alexander HR, Libutti SK, et al. Operative management of islet-cell tumors arising in the head of the pancreas. Surgery. 1998;124:1056–61.CrossRefPubMed Park BJ, Alexander HR, Libutti SK, et al. Operative management of islet-cell tumors arising in the head of the pancreas. Surgery. 1998;124:1056–61.CrossRefPubMed
7.
go back to reference Kahl S, Malfertheiner P. Exocrine and endocrine pancreatic insufficiency after pancreatic surgery. Best Pract Res Clin Gastroenterol. 2004;18:947–55.PubMed Kahl S, Malfertheiner P. Exocrine and endocrine pancreatic insufficiency after pancreatic surgery. Best Pract Res Clin Gastroenterol. 2004;18:947–55.PubMed
8.
go back to reference Lo CY, Lam KY, Kung AW, et al. Pancreatic insulinomas. A 15-year experience. Arch Surg. 1997;132:926–30.PubMed Lo CY, Lam KY, Kung AW, et al. Pancreatic insulinomas. A 15-year experience. Arch Surg. 1997;132:926–30.PubMed
9.
go back to reference Crippa S, Bassi C, Salvia R, et al. Outcomes of pancreatic neoplasms enucleation. Br J Surg. 2007;94:1254–9.CrossRefPubMed Crippa S, Bassi C, Salvia R, et al. Outcomes of pancreatic neoplasms enucleation. Br J Surg. 2007;94:1254–9.CrossRefPubMed
10.
go back to reference de Herder WW, Niederle B, Scoazec JY, et al. Well-differentiated pancreatic tumor/carcinoma: insulinoma. Neuroendocrinology. 2006;84:183–8.CrossRefPubMed de Herder WW, Niederle B, Scoazec JY, et al. Well-differentiated pancreatic tumor/carcinoma: insulinoma. Neuroendocrinology. 2006;84:183–8.CrossRefPubMed
11.
go back to reference Trucker ON, Crotty PL, Conlon KC. The management of insulinoma. Br J Surg. 2006;93:264–75.CrossRef Trucker ON, Crotty PL, Conlon KC. The management of insulinoma. Br J Surg. 2006;93:264–75.CrossRef
12.
go back to reference Müller MW, Friess H, Kleeff J, et al. Middle segmental pancreatic resection: an option to treat benign pancreatic body lesions. Ann Surg. 2006;244:909–18.CrossRefPubMed Müller MW, Friess H, Kleeff J, et al. Middle segmental pancreatic resection: an option to treat benign pancreatic body lesions. Ann Surg. 2006;244:909–18.CrossRefPubMed
13.
go back to reference Falconi M, Mantovani W, Crippa S, et al. Pancreatic insufficiency after different resections for benign tumours. Br J Surg. 2008;95:85–91.CrossRefPubMed Falconi M, Mantovani W, Crippa S, et al. Pancreatic insufficiency after different resections for benign tumours. Br J Surg. 2008;95:85–91.CrossRefPubMed
14.
go back to reference Crippa S, Bassi C, Warshaw AL, et al. Middle pancreatectomy: indications, operative and long-term results. Ann Surg. 2007;246:69–76.CrossRefPubMed Crippa S, Bassi C, Warshaw AL, et al. Middle pancreatectomy: indications, operative and long-term results. Ann Surg. 2007;246:69–76.CrossRefPubMed
15.
go back to reference Aranha GV, Shoup M. Nonstandard pancreatic resections for unusual lesions. Am J Surg. 2005;189:223–8.CrossRefPubMed Aranha GV, Shoup M. Nonstandard pancreatic resections for unusual lesions. Am J Surg. 2005;189:223–8.CrossRefPubMed
16.
go back to reference Balzano G, Zerbi A, Veronesi P, Cristallo M, Di Carlo V. Surgical treatment of benign and borderline neoplasms of the pancreatic body. Dig Surg. 2003;20:506–10.CrossRefPubMed Balzano G, Zerbi A, Veronesi P, Cristallo M, Di Carlo V. Surgical treatment of benign and borderline neoplasms of the pancreatic body. Dig Surg. 2003;20:506–10.CrossRefPubMed
17.
go back to reference Kwekkeboom DJ, Krenning EP, Scheidhauer K, et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: somatostatin receptor imaging with (111)In-pentetreotide. Neuroendocrinology. 2009;90:184–9.CrossRefPubMed Kwekkeboom DJ, Krenning EP, Scheidhauer K, et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: somatostatin receptor imaging with (111)In-pentetreotide. Neuroendocrinology. 2009;90:184–9.CrossRefPubMed
18.
go back to reference O’Toole D, Grossman A, Gross D, et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: biochemical markers. Neuroendocrinology. 2009;90:194–202.CrossRefPubMed O’Toole D, Grossman A, Gross D, et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: biochemical markers. Neuroendocrinology. 2009;90:194–202.CrossRefPubMed
19.
go back to reference Bassi C, Dervenis C, Butturini G, et al. Postoperative pancreatic fistula: an International Study Group (ISGPF) definition. Surgery. 2005;138:8–13.CrossRefPubMed Bassi C, Dervenis C, Butturini G, et al. Postoperative pancreatic fistula: an International Study Group (ISGPF) definition. Surgery. 2005;138:8–13.CrossRefPubMed
20.
go back to reference Heitz PU, Komminoth P, Perren, A et al. Pancreatic endocrine tumours. In: DeLellis RA, Lloyd RV, Heitz PU, Eng C, eds. World Health Organization Classification of Tumors. Pathology and Genetics of Tumors of Endocrine Organs. Lyon: IARC Press; 2004. Heitz PU, Komminoth P, Perren, A et al. Pancreatic endocrine tumours. In: DeLellis RA, Lloyd RV, Heitz PU, Eng C, eds. World Health Organization Classification of Tumors. Pathology and Genetics of Tumors of Endocrine Organs. Lyon: IARC Press; 2004.
21.
go back to reference Rindi G, Kloppel G, Alhman H, et al. TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch. 2006;449:395–401.CrossRefPubMed Rindi G, Kloppel G, Alhman H, et al. TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch. 2006;449:395–401.CrossRefPubMed
22.
go back to reference Pape UF, Jann H, Müller-Nordhorn J, et al. Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors. Cancer. 2008;113:256–65.CrossRefPubMed Pape UF, Jann H, Müller-Nordhorn J, et al. Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors. Cancer. 2008;113:256–65.CrossRefPubMed
23.
go back to reference Arnold R, Chen YJ, Costa F, et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: follow-up and documentation. Neuroendocrinology. 2009;90:227–33.CrossRefPubMed Arnold R, Chen YJ, Costa F, et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: follow-up and documentation. Neuroendocrinology. 2009;90:227–33.CrossRefPubMed
24.
go back to reference Iacono C, Bortolasi L, Serio G. Is there a place for central pancreatectomy in pancreatic surgery? J Gastrointestinal Surg. 1998;2:509–17.CrossRef Iacono C, Bortolasi L, Serio G. Is there a place for central pancreatectomy in pancreatic surgery? J Gastrointestinal Surg. 1998;2:509–17.CrossRef
25.
go back to reference Warshaw AL, Rattner DW, Fernández-del Castillo C, Z’graggen K. Middle segment pancreatectomy: a novel technique for conserving pancreatic tissue. Arch Surg. 1998;133:327–31.CrossRefPubMed Warshaw AL, Rattner DW, Fernández-del Castillo C, Z’graggen K. Middle segment pancreatectomy: a novel technique for conserving pancreatic tissue. Arch Surg. 1998;133:327–31.CrossRefPubMed
26.
go back to reference Fendrich V, Waldmann J, Bartsch DK, Langer P. Surgical management of pancreatic endocrine tumors. Nat Rev Clin Oncol. 2009;6:419–28.CrossRefPubMed Fendrich V, Waldmann J, Bartsch DK, Langer P. Surgical management of pancreatic endocrine tumors. Nat Rev Clin Oncol. 2009;6:419–28.CrossRefPubMed
27.
go back to reference Tonelli F, Fratini G, Nesi G, et al. Pancreatectomy in multiple endocrine neoplasia type 1-related gastrinomas and pancreatic endocrine neoplasias. Ann Surg. 2006;244:61–70.CrossRefPubMed Tonelli F, Fratini G, Nesi G, et al. Pancreatectomy in multiple endocrine neoplasia type 1-related gastrinomas and pancreatic endocrine neoplasias. Ann Surg. 2006;244:61–70.CrossRefPubMed
28.
go back to reference Triponez F, Goudet P, Dosseh D, et al. Is surgery beneficial for MEN1 patients with small (< or =2 cm), nonfunctioning pancreaticoduodenal endocrine tumor? An analysis of 65 patients from the GTE. World J Surg. 2006;30:654–62.CrossRefPubMed Triponez F, Goudet P, Dosseh D, et al. Is surgery beneficial for MEN1 patients with small (< or =2 cm), nonfunctioning pancreaticoduodenal endocrine tumor? An analysis of 65 patients from the GTE. World J Surg. 2006;30:654–62.CrossRefPubMed
29.
go back to reference Gauger PG, Doherty GM, Broome JT, Miller BS, Thompson NW. Completion pancreatectomy and duodenectomy for recurrent MEN-1 pancreaticoduodenal endocrine neoplasms. Surgery. 2009;146:801–6.CrossRefPubMed Gauger PG, Doherty GM, Broome JT, Miller BS, Thompson NW. Completion pancreatectomy and duodenectomy for recurrent MEN-1 pancreaticoduodenal endocrine neoplasms. Surgery. 2009;146:801–6.CrossRefPubMed
30.
go back to reference Balzano G, Zerbi A, Capretti G, et al. Effect of hospital volume on outcome of pancreaticoduodenectomy in Italy. Br J Surg. 2008;95:357–62.CrossRefPubMed Balzano G, Zerbi A, Capretti G, et al. Effect of hospital volume on outcome of pancreaticoduodenectomy in Italy. Br J Surg. 2008;95:357–62.CrossRefPubMed
31.
go back to reference Birkmeyer JD, Stukel TA, Siewers AE, et al. Surgeon volume and operative mortality in the United States. N Engl J Med. 2003;349:2117–27.CrossRefPubMed Birkmeyer JD, Stukel TA, Siewers AE, et al. Surgeon volume and operative mortality in the United States. N Engl J Med. 2003;349:2117–27.CrossRefPubMed
32.
go back to reference Solorzano CC, Lee JE, Pisters PW, et al. Nonfunctioning islet cell carcinoma of the pancreas: survival results in a contemporary series of 163 patients. Surgery. 2001;130:1078–85.CrossRefPubMed Solorzano CC, Lee JE, Pisters PW, et al. Nonfunctioning islet cell carcinoma of the pancreas: survival results in a contemporary series of 163 patients. Surgery. 2001;130:1078–85.CrossRefPubMed
33.
go back to reference Vilar E, Salazar R, Pérez-García J, et al. Chemotherapy and role of the proliferation marker Ki-67 in digestive neuroendocrine tumors. Endocr Relat Cancer. 2007;14:221–32.CrossRefPubMed Vilar E, Salazar R, Pérez-García J, et al. Chemotherapy and role of the proliferation marker Ki-67 in digestive neuroendocrine tumors. Endocr Relat Cancer. 2007;14:221–32.CrossRefPubMed
34.
go back to reference Ferrone CR, Tang LH, Tomlinson J, et al. Determining prognosis in patients with pancreatic endocrine neoplasms: can the WHO classification system be simplified? J Clin Oncol. 2007;25:5609–15.CrossRefPubMed Ferrone CR, Tang LH, Tomlinson J, et al. Determining prognosis in patients with pancreatic endocrine neoplasms: can the WHO classification system be simplified? J Clin Oncol. 2007;25:5609–15.CrossRefPubMed
35.
go back to reference Reber HA. Middle pancreatectomy: why I rarely do it. J Gastrointest Surg. 2007;11:726–9.CrossRef Reber HA. Middle pancreatectomy: why I rarely do it. J Gastrointest Surg. 2007;11:726–9.CrossRef
Metadata
Title
Parenchyma-Preserving Resections for Small Nonfunctioning Pancreatic Endocrine Tumors
Authors
Massimo Falconi, MD
Alessandro Zerbi, MD
Stefano Crippa, MD
Gianpaolo Balzano, MD
Letizia Boninsegna, MD
Vanessa Capitanio, MD
Claudio Bassi, MD
Valerio Di Carlo, MD
Paolo Pederzoli, MD
Publication date
01-06-2010
Publisher
Springer-Verlag
Published in
Annals of Surgical Oncology / Issue 6/2010
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-010-0949-8

Other articles of this Issue 6/2010

Annals of Surgical Oncology 6/2010 Go to the issue